Breaking News

Perrigo Acquires Remaining Stake In Cobrek

December 28, 2012

Expands position in topical foam-based generics

Perrigo has signed and completed a definitive merger agreement, acquiring the remaining stake in Cobrek Pharmaceuticals, Inc., a privately-held drug development company, for approximately $45 million on a cash free and debt free basis.
In May 2008, Perrigo acquired an 18.5% minority stake in Cobrek and entered a product development collaboration focused on foam dosage form generic pharmaceutical products. The partnership has successfully yielded two commercialized foam-based products and two FDA approved foam-based products to be launched in Perrigo's fiscal year 2013. Cobrek earns revenues from a profit sharing agreement on partnered products and Perrigo is responsible for all commercial activities under the existing collaboration.
Perrigo chairman, president and chief executive officer, Joseph C. Papa said, "We continue to market the only generic foam products in the U.S. and expect to launch two additional products – generic versions of Luxiq (betamethasone valerate) Foam and Olux-E (clobetasol propionate) Foam 0.05% – during this fiscal year, which is a testament to the challenges of this dosage form and success of our partnership with Cobrek. Acquiring the remaining stake of Cobrek not already owned is the logical next step in this relationship and will allow us to continue to bring quality, affordable healthcare to our consumers and customers."
blog comments powered by Disqus
  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • The Role of Alliances in Modern Drug Development

    The Role of Alliances in Modern Drug Development

    Dr. Claire Madden-Smith, Senior Vice President, Juniper Pharma Services||September 8, 2016
    Combining expertise to get drug candidates through development

  • Successful Method Transfer of Solid Oral Dosage

    Successful Method Transfer of Solid Oral Dosage

    John Frankonis, Ropack Pharma Solutions||June 2, 2016
    The three steps outlined will help guide the process of completing a successful analytical method transfer